MCI Onehealth Partners with MDClone to Accelerate Research through Global Clinical Intelligence Offering

TORONTO, July 28, 2022 (GLOBE NEWSWIRE) -- MCI Onehealth Technologies Inc. ("MCI") (TSX: DRDR), a clinician-led healthcare technology company focused on increasing access to and quality of healthcare, and MDClone, a digital health company and leader in synthetic data, are pleased to announce an advanced clinical intelligence offering for their global partners. This offering combines real-world health insights with mirrored synthetic data to power deeper research and inspire novel therapeutic development.

"MCI's collaboration with MDClone will provide our partners with greater access to high-value data-insights-as-a-service for an array of research, clinical and data science needs," said Dr. Alexander Dobranowski, MD, Chief Executive Officer of MCI. "Whether through MCI's clinic network, international healthcare providers, or pharmaceutical, life sciences and biotech partners, our mutually enhanced insights will help to quickly translate healthcare data and research into improved health and quality of life for patients."

The real-world patient health journeys that MCI's tech-enabled network is able to capture offer a comprehensive picture to researchers, who can benefit from a fuller perspective. The partnership between MCI and MDClone will leverage MDClone's technology to load, organize and protect MCI-generated patient data and use this data to help find insights to improve care. In addition, MCI and MDClone intend to work together to improve data collection and curation to better serve the needs of applied healthcare research.

MDClone offers clients robust, detailed data for thorough end-to-end, real-world analysis. Using the MDClone ADAMS Platform analytics tools and synthetic data capabilities, clinicians, researchers, and healthcare professionals can explore healthcare data more efficiently to accelerate real-world evidence processes. With synthetic data capabilities at the forefront, users can leverage self-service tools to access, analyze, and share information without privacy concerns. Additionally, the real-time identification and extraction of information about a specific population of interest allows users at healthcare systems to overcome some of the common barriers that can slow clinical data projects' progress.

"We're thrilled to partner with innovators like MCI in the healthcare and life science industries and beyond. Together, we can provide tailored clinical insights that meet clients' needs, and from those insights, MDClone can generate synthetic data that researchers can use to better understand disease progression, enhance care delivery, and develop new products that can improve patient outcomes," said Josh Rubel, Chief Operating Officer of MDClone.

In keeping with its objective to be a preeminent health technology leader, MCI nurtures international opportunities to leverage its vast pool of high-quality structured clinical information. The MDClone ADAMS Platform's unique ability to convert datasets and cohorts of interest into synthetic files that are statistically comparable to the original data, but composed entirely of artificial patients, aids in broader and more secure access and opens the doors to third-party access and larger-scale research impact.

MCI's audience for health insights continues to grow in Canada and will further benefit from access to MDClone's global roster of top-tier health system and pharma relationships. The collaboration with MDClone will accelerate MCI's entry into the clinical insights and analytics sectors in the United States of America and Israel, including potential access to headquarter-level decision-makers of global pharma and life science leaders.

"Through this commercial arrangement, we each have the benefit of immediate introduction to the active client rosters of the other, and we each gain a superior ? and unique ? offering to acquire new partners, fueling the expansion of MCI's health insight services into international markets," added Dr. Dobranowski.

About MCI

MCI is a healthcare technology company focused on empowering patients and doctors with advanced technologies to increase access, improve quality, and reduce healthcare costs. As part of the healthcare community for over 30 years, MCI operates one of Canada's leading primary care networks with nearly 260 physicians and specialists, serves more than one million patients annually and had nearly 300,000 telehealth visits last year, including online visits via mciconnect.ca. MCI additionally offers an expanding suite of occupational health service offerings that support a growing list of nearly 600 corporate customers. Led by a proven management team of doctors and experienced executives, MCI remains focused on executing a strategy centered around acquiring technology and health services that complement the company's current roadmap. For more information, visit mcionehealth.com.

About MDClone

MDClone offers an innovative, self-service data analytics environment powering exploration, discovery, and collaboration throughout healthcare ecosystems cross-institutionally and globally. The powerful underlying infrastructure of the MDClone ADAMS Platform allows users to overcome common barriers in healthcare in order to organize, access, and protect the privacy of patient data while accelerating research, improving operations and quality, and driving innovation to deliver better patient outcomes. Founded in Israel in 2016, MDClone serves major health systems, payers, and life science customers in the United States, Canada, and Israel. Visit mdclone.com for more information.

For media enquiries please contact:
Nolan Reeds | MCI Onehealth | [email protected]
Erin Giegling | MDClone | [email protected]

Forward Looking Statements

Certain statements in this press release, constitute "forward-looking information" and "forward looking statements" (collectively, "forward looking statements") within the meaning of applicable Canadian securities laws and are based on assumptions, expectations, estimates and projections as of the date of this press release. Forward-looking statements in this press release include statements with respect to the anticipated technological and strategic benefits of MCI's partnership and offering with MDClone, as well as MCI's future growth, strategic plan, results of operations, performance and business prospects and opportunities, in general. The words "plans", "expects", "nurtures", "projected", "estimated", "forecasts", "anticipates", "intend", "potential", "prospects", "seek", "aim", "strategy", "targets" or "believes", "for use in", "growth", "expansion", "develop", "to find", "to accelerate", "to overcome", "to better understand", "to leverage", "to convert", "to grow", "to be", "future", "later", "continues to", "facilitate", or variations of such words and phrases or statements that certain future conditions, actions, events or results "will", "may", "could", "would", "should", "might" or "can", or negative versions thereof, "occur", "continue" or "be achieved", and other similar expressions, identify forward-looking statements. Forward-looking statements are necessarily based upon management's perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by MCI as of the date of such statements, are outside of MCI's control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward looking statements contained in this press release are based on various assumptions, including, but not limited to, the following: MCI's ability to achieve its growth strategy; the demand for MCI's products and fluctuations in future revenues; the availability of future business ventures, commercial arrangements and acquisition targets or opportunities and MCI's ability to consummate them; the effects of competition in the industry; the requirement for increasingly innovative product solutions and service offerings; trends in customer growth; sufficiency of current working capital to support future operating and working capital requirements; the stability of general economic and market conditions; currency exchange rates and interest rates; equity and debt markets continuing to provide MCI with access to capital; MCI's ability to comply with applicable laws and regulations; MCI's continued compliance with third party intellectual property rights; the anticipated effects of the COVID-19 pandemic; and that the risk factors noted below, collectively, do not have a material impact on MCI's business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved.

Known and unknown risk factors, many of which are beyond the control of MCI, could cause the actual results of MCI to differ materially from the results, performance, achievements or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled "Risk Factors" in MCI's annual information form dated March 31, 2022, each of which is available under MCI's SEDAR profile at www.sedar.com. The risk factors are not intended to represent a complete list of the factors that could affect MCI and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. MCI disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements.